LB-75

Introduction: Vascular endothelial growth factor (VEGF) is a pro-angiogenic molecule that is elevated in patients with metastatic ocular melanoma. We hypothesized that administration of bevacizumab (Bev), a monoclonal antibody that neutralizes VEGF, in combination with high-dose interferon alfa-2b (IFN-a2b), an inhibitor of basic fibroblast growth factor (FGF), would lead to the regression of metastatic disease.
 Methods: Patients with metastatic ocular melanoma received Bev (15 mg/kg iv every 2 weeks) plus IFN-a2b (5 MU/m2 sc three times weekly for 2 weeks followed by a dose of 10MU/m2 sc thereafter). Patients exhibiting a clinical response or stable disease after 12 weeks were treated until disease progression.
 Results: 5 patients were accrued (3 male, 2 female). Their mean age was 63.8 years (range 53-71 years). Given the potential for thromboembolic complications with Bev, patients were aggressively screened for coagulation abnormalities. Overall the regimen was well tolerated. The following adverse events were noted: grade 3 dyspnea (2 patients), grade 3 fatigue (1), grade 4 fatigue (1), grade 3 muscle weakness (1), grade 3 anorexia (1), grade 3 diarrhea (1). Three patients had stable disease at 8, 10 and 15 weeks each. Two patients failed to respond and progressed at 6 and 7 weeks respectively.
 Conclusion: Bev and IFN were well tolerated at these doses and disease stabilization was achieved in several patients. This drug combination deserves to be examined further in this setting.

99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA